Pharmaceuticals & Therapeutics

The biotech plans to separate its R&D pipeline from its booming royalty assets, creating two public companies and winning applause from Wall Street.

The nation's leading aesthetic provider launches a Salmon DNA Facial, XTherma, and NAD+ injections, betting on the science of regenerative beauty.

The acquisition signals a major trend: investors are banking on professional skincare and the mature consumer. Here's what the deal means for the industry.

The D.C. transplant institute surpasses a historic milestone, pioneering new tech and giving thousands a second chance at life amid a national organ shortage.

A unique $4M award program aims to solve a critical funding gap, accelerating high-risk, high-reward cancer therapies from academic labs to patients.

Known for baked makeup, Laura Geller Beauty launches a cream palette, targeting women 40+ with a hydrating formula and a star-studded, age-positive campaign.

With a soaring stock and a breakthrough CAR-T therapy, Immix Biopharma is set to capture investor attention. What's behind the hype for its lead drug, NXC-201?

Daxor reports a transformative year with 45% revenue growth, a new FDA-cleared portable analyzer, and a full pivot to a high-growth medtech company.

As Akebia heads to a major conference, investors watch its Vafseo launch, new rare disease pipeline, and path to profitability. Here's what's at stake.

A new survey reveals a silent public health crisis as millions of Canadians face chronic sleep loss, with many admitting to driving while dangerously tired.

After a kidney trial setback, CalciMedica's lead drug Auxora shows strong promise for acute pancreatitis, but a tight cash runway looms over its future.

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.

Esperion's $75M+ deal for Corstasis and its novel nasal diuretic, Enbumyst, targets a $4B market and a new era of at-home edema management.

MAIA Biotechnology secured a crucial $30M to advance its promising lung cancer drug, but the move sent its stock plunging amid investor fears of dilution.

A federal policy loophole is diverting billions from struggling rural providers to wealthy urban hospitals, threatening care for millions of Americans.

A next-gen drug for chronic hives shows superior, faster results than the long-standing standard of care, heralding a potential shift in allergy treatment.

A new study aims to confirm a novel immunotherapy's dramatic results in colorectal cancer, offering hope for patients with limited treatment options.

Amorepacific's research-backed brand IOPE arrives at Sephora, challenging the US anti-aging market with patented technology and accessible pricing.

DRI Healthcare's strategic C$109M debt swap lowers interest costs, extends maturity, and signals strong investor confidence to fuel its acquisition pipeline.

A global coalition of advocates, doctors, and pharma giants launches Obesity Care Week, aiming to dismantle systemic barriers and fight pervasive weight bias.